IP Library Patent Application 14336357
Patent Application
App. No. 14/336,357

METHOD AND APPARATUS FOR DISPOSAL OF A PHARMACEUTICAL PRODUCT BLISTER CARD

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/336,357
Abstract

A pharmaceutical product supply including primary packaging (e.g., a blister card) having a plurality of receptacles and pharmaceutical product (e.g., one or more pills, capsules, etc.) enclosed within at least one of the receptacles. Heating the pharmaceutical product supply to at least an activation temperature of a heat-activated encapsulation material associated with the supply may encapsulate the pharmaceutical product to reduce the likelihood that the pharmaceutical product can thereafter be administered, and thereby facilitates disposal of the pharmaceutical product. In one embodiment, a tray of a primary packaging is constructed of the heat-activated encapsulation material. In another embodiment, primary packaging may be disposed within a cavity of secondary packaging (e.g., carton), and the heat-activated encapsulation material may be in the form of a layer that is also located within the cavity.

Claims (23)

1 . A method of disposing pharmaceutical product, comprising:

heating pharmaceutical product packaging, wherein said pharmaceutical product packaging comprises a plurality of receptacles and an encapsulation material, wherein unused pharmaceutical product is enclosed within at least one of said plurality of receptacles by said pharmaceutical product packaging prior to said heating, wherein said heating is to at least an activation temperature of said encapsulation material, and wherein said heating comprises melting said encapsulation material and flowing said encapsulation material onto said each said unused pharmaceutical product within said pharmaceutical product packaging; and

cooling said encapsulation material after said heating to lock said unused pharmaceutical product within said encapsulation material to at least substantially encapsulate said unused pharmaceutical product within said pharmaceutical product packaging.

2 . The method of claim 1 , wherein said pharmaceutical product packaging contacts said pharmaceutical product prior to said heating.

3 . The method of claim 1 , wherein said pharmaceutical product packaging comprises primary packaging.

4 . The method of claim 3 , wherein said primary packaging comprises a tray and a covering that is sealed to said tray, wherein said tray comprises said plurality of receptacles, and wherein said heating is initiated with said cover already having been sealed to said tray.

5 . The method of claim 4 , wherein said tray comprises a formed plastic tray.

6 . The method of claim 4 , wherein said covering is selected from the group consisting of a film, a foil, paper, and any combination thereof.

7 . The method of claim 6 , wherein said covering is non-metallic.

8 . The method of claim 4 , wherein said covering is sealed to a surface of said tray that comprises said plurality of receptacles.

9 . The method of claim 4 , wherein at least one of said tray and said covering comprises said heat-activated encapsulation material.

10 . The method of claim 9 , wherein said tray comprises said heat-activated encapsulation material.

11 . The method of claim 1 , wherein an entirety of said pharmaceutical product packaging is non-metallic.

12 . The method of claim 1 , wherein said pharmaceutical product packaging comprises a blister card.

13 . The method of claim 1 , further comprising:

positioning said pharmaceutical product packaging in a container prior to said heating, wherein said heating is executed with said pharmaceutical product packaging being in said container.

14 . The method of claim 13 , wherein said pharmaceutical product packaging comprises primary packaging and wherein said container comprises secondary packaging.

15 . The method of claim 1 , further comprising:

configuring said pharmaceutical product packaging for disposal, wherein said configuring comprises said heating and said cooling.

16 . The method of claim 15 , further comprising:

disposing said pharmaceutical product packaging after said heating and said cooling.

17 . The method of claim 1 , further comprising:

disposing said pharmaceutical product packaging after said heating and said cooling.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 039237, FRAME 0147 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0902 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jul 1, 2016
From: MALLINCKRODT LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 039237/0147 →